Picture EBD Group World of Partnering Opportunities 650x100px
Product › Details

GlycoConnect™ site-specific antibody-conjugation technology

Products Next higher product group antibody-drug conjugates (ADC) technology
Period Status 2019-04-15 existent
Organisation Organisation Synaffix B.V.
  Group Lonza (Group)

Synaffix B.V.. (4/10/19). "Press Release: Synaffix Announces $125m License Agreement with Shanghai Miracogen". Amsterdam.

Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs.

Under the terms of the agreement, Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in its next clinical candidate. Synaffix is eligible to receive upfront and potential milestone payments that total $125 million, plus royalties.

Miracogen will be responsible for the research, development, manufacturing and commercial-ization of the ADC product while Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect™ and HydraSpace™ technologies.

This agreement follows a research collaboration between the two companies which was centered around a specific drug candidate that has now been selected for clinical development.

Mary Hu, Chairman and CEO of Miracogen, said:

“We are very pleased to have reached this license agreement with Synaffix. We believe that their GlycoConnect™ and HydraSpace™ technologies will further differentiate our pipeline of ADCs by delivering valuable expansion of the therapeutic index. Our efficient and collaborative relationship during the research phase has provided us with a highly competitive new asset for the Miracogen pipeline in just a five-month timeframe. We look forward to continuing our collaboration as we advance this candidate into the clinic and beyond to benefit cancer patients.”

Peter van de Sande, CEO of Synaffix, said:

“Working with Miracogen has been a rewarding experience. As we transition into the development phase together, this license agreement with Miracogen provides additional validation of our GlycoConnect™ and HydraSpace™ technologies.”

“There is a clear trend in China towards developing innovative products and as such, ADCs have emerged as a strong area of growth within the field of oncology. Our proprietary technologies can address the current unmet need for clinical candidates with an enhanced therapeutic index, thereby driving further growth of our activities in China and other markets.”

About GlycoConnect™ and HydraSpace™

The clinical-stage GlycoConnect™ and HydraSpace™ technologies enable best-in-class ADCs with significantly enhanced efficacy and tolerability. GlycoConnect™ is the conjugation technology that exploits the native glycan for site-specific and stable payload attachment. HydraSpace™ is the compact and highly polar spacer technology. These technologies can be applied directly to any existing antibody without any protein engineering and are compatible with all ADC payload classes.

The growing experience of Synaffix and its collaboration partners continues to confirm the ability of GlycoConnect™ and HydraSpace™ to consistently generate ADCs that are more effective and better tolerated when compared to the three major clinical-stage ADC conjugation technologies.

About Synaffix B.V.

Synaffix B.V. is a Dutch biotechnology company that enables highly competitive ADC product candidates using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and the ADC-enhancing HydraSpace™ technology, the extension of the platform with toxSYN™ payloads provides a fully complimentary technology platform that enables any company with an antibody to develop superior, proprietary ADC products.

The Synaffix platform comes with an IND-ready CMC package to support a rapid timeline to the clinic. Granted patents covering Synaffix’s technology provide end-to-end protection of the platform technology as well as resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing as exemplified through deals with ADC Therapeutics and Mersana Therapeutics.

Synaffix is backed by a top tier, European, life science-focused investor syndicate that includes Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

Record changed: 2023-07-10


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for GlycoConnect™ site-specific antibody-conjugation technology

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top